Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYD-101 Ophthalmic Solution for Treatment of Myopia in Children
2018-004775-13Phase 3Active
- Sponsor
- Sydnexis Inc.
- Start
- May 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SYD-101 in myopia (4 arms), sponsored by Sydnexis Inc. Primary endpoint: Primary efficacy endpoint (EU). Started May 2019; status: active.
02
Drugs
SYD-101
03
Conditions
myopia
Beyond the preview
Go deeper on 2018-004775-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004775-13.